^
Association details:
Biomarker:STK11 mutation
Cancer:Solid Tumor
Drug Class:Immunotherapy
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Biomarker development 40P - Interplay between Mutational Profile and TMB on overall survival: A Posthoc Analysis of 1,662 Metastatic Patients Treated with Immune Checkpoint Inhibitors.

Published date:
12/02/2021
Excerpt:
From that same TMB cutoff, a Cox multivariate analysis stratified by median TMB revealed that mutations in STK11 (HR 2.95; p<0.0007) and TP53 (HR 1.89; p<0.0032) were associated with a higher risk of death. Otherwise, mutations in TERT (HR 0.54; p<0.0044) and NOTCH3 (HR 0.23; p<0.0355) were protective.... the mutational profile can contribute to define outcomes to ICIs.